Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 516

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Cardiac amyloidosis

Not recruiting

Study on the Effects and Safety of Coramitug for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eye103

Study on the Effects of CAL101 for Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:CAL101

Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:PUCOTENLIMAB

Cardiac amyloidosis

Not recruiting

Study on the Effects and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alxn2220

Migraine

Not recruiting

Study on the Effects of Cilostazol on Headaches in Men and Women with Migraine Without Aura

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:CILOSTAZOL

Study on the Effects of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Placebo

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab

Study of Felzartamab for Patients with Late Antibody-Mediated Rejection After Kidney Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)

Hepatitis D

Not recruiting

Study on BJT-778 for Patients with Chronic Hepatitis Delta Infection

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bjt-778

Glioblastoma+1

Not recruiting

Study on the Safety of Photodynamic Therapy with Aminolevulinic Acid Hydrochloride for Patients Aged 18-75 with Grade IV Glioblastoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.